Skip to main content
. 2023 Jul 10;72(10):3217–3228. doi: 10.1007/s00262-023-03489-1

Table 1.

Immune-related adverse events

Adverse event Before third vaccine dose, N = 56 (100%) After third vaccine dose, N = 56 (100%) P value Low-Ra, N = 26 (100%) High-Rb, N = 30 (100%) P value
N (%) CTCAE Grading N (%) CTCAE Grading N (%) N (%)
Thyroiditis 8 (14.3%) 1–2 3 (5.3%) 2–3 0.13 2 (7.7%) 9 (30%) 0.036
Skin rash 4 (7.1%) 1–2 1 (1.8%) 2 0.17 2 (7.7%) 3 (10%) 0.76
Pancreatitis 3 (5.3%) 2 1 (1.8%) 2 0.31 3 (11.5%) 1 (3.3%) 0.23
Colitis 3 (5.3%) 2 1 (1.8%) 2 0.31 1 (3.8%) 3 (10%) 0.37
Hepatitis 2 (3.5%) 2 1 (1.8%) 2 0.56 1 (3.8%) 2 (6.6%) 0.63
Pneumonitis 2 (3.5%) 2 0.15 2 (6.6%) 0.17
Arthritis 2 (3.5%) 1–2 2 (3.5%) 2 1.00 2 (7.7%) 2 (6.6%) 0.88
Myositis 1 (1.8%) 2 0.31 1 (3.3%) 0.34
Vasculitis 1 (1.8%) 3 0.31 1 (3.8%) 0.27
Uveitis 1 (1.8%) 2 0.31 1 (3.3%) 0.34

CTCAE common terminology criteria for adverse events, version 5.0

aLow-R indicates the subgroup of patients with an anti-RBD-S1 IgG titer < 486 BAU/mL after the third dose of vaccine

bHigh-R indicates the subgroup of patients with an anti-RBD-S1 IgG titer ≥ 486 BAU/mL after the third dose of vaccine,

Statistical significance not maintained after Holm-Bonferroni p value correction for multiple comparisons